Compare Mesoblast Limited (MESO) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Open Text Corporation — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Open Text Corporation trades at $23.1 (market cap $5.61B). The key difference: Open Text Corporation is far larger — about 3.2× Mesoblast Limited's market cap, and Open Text Corporation pays a 4.82% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Open Text Corporation for 23 Days on average.
| MESO | OTEX | |
|---|---|---|
Market Cap | $1.75B | $5.61B |
Volume | 239,027 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $20.96 | $39.69 |
52-Week Low | $13.19 | $20.01 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $1.83B | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
OpenText (OTEX) trades at $23.14, up 1.89% today, with strong technical momentum indicated by a bullish overall signal. The company demonstrates robust fundamentals with consistent earnings beats, posting Q2 2026 EPS of $1.23 versus $1.02 expected, and maintains healthy profitability with 12.26% net income margin. Recent corporate actions include a $1 billion senior secured notes offering and strategic AI partnerships, signaling growth initiatives.
The stock presents an attractive valuation opportunity with P/E of 9.01 and P/S of 1.1 below sector averages, supported by analyst consensus target of $28.30 implying 22% upside. Key risks include high debt levels at $6.34 billion and competitive pressures in the software sector. Institutional sentiment remains mixed with 42% buy ratings amid ongoing debt management efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
